Diabetes is a rapidly growing health concern in Southeast Asia, with millions of individuals affected by this chronic condition. Early diagnosis and effective management are crucial in preventing complications and improving the quality of life for those living with diabetes. Recognizing this urgent need, Eli Lilly and Goldsite have committed to providing innovative solutions that can be easily deployed in resource-limited settings.

The Role of Goldsite’s POCT Analyzer GPP-100

Goldsite’s portable POCT Analyzer GPP-100 has been a game-changer in clinical diagnostics, especially for diabetes care. Utilizing nephelometry technology, with an all-in-one cartridge design, GPP-100 allows for rapid and accurate screening of 23 assays including HbA1c, a critical marker for long-term blood glucose control.

The analyzer’s portability and ease of use make it ideal for deployment in remote and underserved areas, where access to traditional laboratory facilities is often limited.

(A4D volunteer, Eli Lilly employees, and the doctor with GPP-100. Dr. Manivong is holding GPP-100, Source: Eli Lilly Website)

In Laos, Action4Diabetes (A4D) has been utilizing this technology to conduct quick and efficient screenings. The ability to obtain immediate results enables healthcare providers to make timely decisions and offer appropriate interventions, significantly improving patient outcomes.

Eli Lilly’s Commitment to Diabetes Awareness

Eli Lilly, a global leader in diabetes care, has been at the forefront of efforts to raise awareness and improve diabetes management worldwide. Through its 30x30 program, Eli Lilly aims to enhance healthcare for 30 million people in resource-limited settings by 2030. The collaboration with Goldsite aligns perfectly with this mission, as it focuses on making advanced diagnostic tools accessible to those who need them most.

Joint Efforts in Southeast Asia

Last year in Bangkok, Thailand at  Medlab Asia Expo 2023 a key IVD laboratory and healthcare industry event in Southeast Asia, Goldsite attended as an exhibitor, bringing innovative HbA1c testing solutions, like GPP-100 Specific Protein Analyzer, A1c Go POCT HbA1c Analyzer based on boronate affinity chromatography methodology and GSH-60 HbA1c Analyzer based on HPLC (High-Performance Liquid Chromatography).

The rapid pace of urbanization across Southeast Asia has resulted in increased demand for quality healthcare services. Robust healthcare infrastructure is essential to cater to the growing urban populations, ensuring that healthcare remains accessible and efficient. This requires that the medical instruments are not only swift and precise but also can be easily deployable and accessible across both urban centers and remote locations. Goldsite’s HbA1c series has earned both NGSP (National Glycohemoglobin Standardization Program) and IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) certifications, ensuring its accuracy and consistency across varied clinical settings.

(Goldsite's Specific Protein Analyzer GPP-100 is still well functioning 5 years after its installation at UCMed, an affiliated medical center of the University of Cebu School of Medicine, which is the largest privately-held educational institution in the Philippines.)

A Brighter Future for Diabetes Care

Eli Lilly and Action4Diabetes (A4D) deserve special recognition for their remarkable efforts in Laos, where they have tirelessly promoted diabetes awareness and improved the quality of life for those living with diabetes. Their dedication has made a profound impact on countless lives, and Goldsite is more than satisfied to be part of this joint effort. Looking ahead, Goldsite envisions delivering high-quality solutions globally, continuing to innovate and collaborate to address healthcare challenges worldwide

Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, Indiana, is a global pharmaceutical leader dedicated to improving lives through innovative medicines. Renowned for being the first to mass-produce insulin, Lilly remains at the forefront of diabetes care with a comprehensive portfolio of treatments like Humalog, Trulicity, and Jardiance. Their commitment extends beyond medication to include extensive research, clinical trials, and initiatives like the 30x30 program, which aims to enhance healthcare for 30 million people in resource-limited settings by 2030. With operations in over 125 countries, Lilly collaborates globally to ensure their treatments reach those in need, continually striving to make high-quality healthcare accessible and affordable.

GOLDSITE DIGANOSTICS INC. is a leading manufacturer of IVD products dedicated to the healthcare sector. With over 25 years of expertise in the IVD industry, Goldsite has established itself as a trusted partner since 1999. With a team of experts in the field of diagnostics technology and a passion for improving healthcare, we strive to bring cutting-edge products to market that meet the evolving needs of health providers and patients. Engaged in R&D, manufacturing, and marketing of clinical laboratory devices and reagents, Goldsite has a portfolio of products covering specific proteins, chemistry, chemiluminescence, POCT platform, and associated reagents. All products live up to global standards with CE marking and have been exported to over 100+ countries.

Follow Us

For more information about Goldsite Diagnostics Inc. , please visit: www.goldsite.com.cn

Follow our social media channels on Linkedin, X/Twitter, Facebook, Instagram, TikTok, and YouTube, and stay tuned for our latest news!